Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio Inc (NQ: CABA )

7.000 -0.090 (-1.27%)
Streaming Delayed Price Updated: 11:50 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,309
Open 7.150
Bid (Size) 7.000 (3)
Ask (Size) 7.020 (6)
Prev. Close 7.090
Today's Range 6.950 - 7.277
52wk Range 6.900 - 26.35
Shares Outstanding 31,355,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
From Cabaletta Bio
Via GlobeNewswire

Performance

YTD
-68.41%
-68.41%
1 Month
-17.45%
-17.45%
3 Month
-47.45%
-47.45%
6 Month
-65.80%
-65.80%
1 Year
-44.36%
-44.36%

More News

Read More
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Recap: Cabaletta Bio Q4 Earnings
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 12/8
Via Investor Brand Network
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024
Via InvestorPlace
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Cabaletta Bio
Via GlobeNewswire
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023
Via InvestorPlace
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
Via Benzinga
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Cabaletta Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.